Song Joon Young, Lim Jae Hyang, Lim Sangyong, Yong Zhi, Seo Ho Seong
a Department of Internal Medicine , Korea University College of Medicine , Seoul , Republic of Korea.
b Department of Microbiology , College of Medicine, Ewha Womans University , Seoul , Republic of Korea.
Hum Vaccin Immunother. 2018;14(11):2669-2681. doi: 10.1080/21645515.2018.1493326. Epub 2018 Jul 16.
(group B , GBS) is a leading cause of severe invasive disease in neonate, elderly, and immunocompromised patients worldwide. Despite recent advances in the diagnosis and intrapartum antibiotic prophylaxis (IAP) of GBS infections, it remains one of the most common causes of neonatal morbidity and mortality, causing serious infections. Furthermore, recent studies reported an increasing number of GBS infections in pregnant women and elderly. Although IAP is effective, it has several limitations, including increasing antimicrobial resistance and late GBS infection after negative antenatal screening. Maternal immunization is the most promising and effective countermeasure against GBS infection in neonates. However, no vaccine is available to date, but two types of vaccines, protein subunit and capsular polysaccharide conjugate vaccines, were investigated in clinical trials. Here, we provide an overview of the GBS vaccine development status and recent advances in the development of immunoassays to evaluate the GBS vaccine clinical efficacy.
B组链球菌（GBS）是全球新生儿、老年人和免疫功能低下患者严重侵袭性疾病的主要病因。尽管近年来GBS感染的诊断和产时抗生素预防（IAP）取得了进展，但它仍然是新生儿发病和死亡的最常见原因之一，会引发严重感染。此外，最近的研究报告称，孕妇和老年人中GBS感染的数量在增加。虽然IAP有效，但它有几个局限性，包括抗菌耐药性增加以及产前筛查阴性后的迟发性GBS感染。母体免疫是预防新生儿GBS感染最有前景和有效的对策。然而，迄今为止尚无可用疫苗，但在临床试验中对两种疫苗进行了研究，即蛋白亚单位疫苗和荚膜多糖结合疫苗。在此，我们概述了GBS疫苗的开发状况以及评估GBS疫苗临床疗效的免疫测定方法的最新进展。
